US Skin Cancer Drug Pipeline Analysis

Publish Date:- Jan-2014       No Of Pages (310)

Electronic Access - Single User License $1200 Buy Now
CD-ROM Mail Delivery $1500Buy Now
Hard Copy Mail Delivery $1800 Buy Now
Electronic Access - Multi-User License $2400 Buy Now


The market for skin cancer in the US is expected to grow significantly owing to reasons like increasing number of patients and entry of new therapies which are in the pipeline. Additionally, the organic growth of key marketed drugs is also another major factor driving the growth in the US market. Of the different types of skin cancers in the US, Melanoma is the most common. Though this segment accounts for just 5% of the overall US skin cancer market, it is a major factor causing 75% deaths in the region. Also, the US market witnesses a greater use of adjuvant therapy to treat early stage melanoma, as compared to the other regions.

With surgery being along with early detection is by far the most successful method of treating skin cancer in the US, the risk of recurrence in the patients is high. Additionally, the survival rates for the patients with advanced stages of the disease are very low. This has been a major challenge in the US market and companies investing in this space have been continuously researching on various options to improve the survival rates.

US Skin Cancer Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of skin cancer in US. Research report covers all drugs being developed in various development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the US skin cancer drug market based upon development process.

Following parameters for each drug profile in development phase are covered in “US Skin Cancer Drug Pipeline Analysis” research report:

• Drug Profile Overview

• Alternate Names for Drug

• Active Indication

• Phase of Development

• Mechanism of Action

• Brand Name

• Patent Information

• Orphan Designation by Indication, Country & Organisation

• Country for Clinical Trial

• Owner / Originator/ Licensee/Collaborator

• Administrative Route

• Drug Class

• ATC Codes



Number of Skin Cancer Drug in Pipeline by Clinical Phase:

• Research: 3

• Preclinical: 29

• Clinical: 5

• Phase 0: 1

• Phase-I: 29

• Phase-I/II: 18

• Phase-II: 41

• Phase-III: 13

• Registered: 4

• Marketed: 18

• Unknown: 1


The market for skin cancer in the US is expected to grow significantly owing to reasons like increasing number of patients and entry of new therapies which are in the pipeline. Additionally, the organic growth of key marketed drugs is also another major factor driving the growth in the US market. Of the different types of skin cancers in the US, Melanoma is the most common. Though this segment accounts for just 5% of the overall US skin cancer market, it is a major factor causing 75% deaths in the region. Also, the US market witnesses a greater use of adjuvant therapy to treat early stage melanoma, as compared to the other regions.

With surgery being along with early detection is by far the most successful method of treating skin cancer in the US, the risk of recurrence in the patients is high. Additionally, the survival rates for the patients with advanced stages of the disease are very low. This has been a major challenge in the US market and companies investing in this space have been continuously researching on various options to improve the survival rates.

US Skin Cancer Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of skin cancer in US. Research report covers all drugs being developed in various development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the US skin cancer drug market based upon development process.

Following parameters for each drug profile in development phase are covered in “US Skin Cancer Drug Pipeline Analysis” research report:

• Drug Profile Overview

• Alternate Names for Drug

• Active Indication

• Phase of Development

• Mechanism of Action

• Brand Name

• Patent Information

• Orphan Designation by Indication, Country & Organisation

• Country for Clinical Trial

• Owner / Originator/ Licensee/Collaborator

• Administrative Route

• Drug Class

• ATC Codes



Number of Skin Cancer Drug in Pipeline by Clinical Phase:

• Research: 3

• Preclinical: 29

• Clinical: 5

• Phase 0: 1

• Phase-I: 29

• Phase-I/II: 18

• Phase-II: 41

• Phase-III: 13

• Registered: 4

• Marketed: 18

• Unknown: 1

1. US Skin Cancer Drug Market Overview



2. Skin Cancer Drug Clinincal Phase: Unknown

  2.1 Overview

  2.2 Skin Cancer Drug Profile in Clinical Phase



3. Skin Cancer Drug Clinincal Phase: Research

  3.1 Overview

  3.2 Skin Cancer Drug Profile in Clinical Phase



4. Skin Cancer Drug Clinincal Phase: Preclinical

  4.1 Overview

  4.2 Skin Cancer Drug Profile in Clinical Phase



5. Skin Cancer Drug Clinincal Phase: Clinical

  5.1 Overview

  5.2 Skin Cancer Drug Profile in Clinical Phase



6. Skin Cancer Drug Clinincal Phase: Phase-0

  6.1 Overview

  6.2 Skin Cancer Drug Profile in Clinical Phase



7. Skin Cancer Drug Clinincal Phase: Phase-I

  7.1 Overview

  7.2 Skin Cancer Drug Profile in Clinical Phase



8. Skin Cancer Drug Clinincal Phase: Phase-I/II

  8.1 Overview

  8.2 Skin Cancer Drug Profile in Clinical Phase



9. Skin Cancer Drug Clinincal Phase: Phase-II

  9.1 Overview

  9.2 Skin Cancer Drug Profile in Clinical Phase



10. Skin Cancer Drug Clinincal Phase: Phase-III

  10.1 Overview

  10.2 Skin Cancer Drug Profile in Clinical Phase



11. Skin Cancer Drug Clinincal Phase: Registered

  11.1 Overview

  11.2 Skin Cancer Drug Profile in Clinical Phase



12. Marketed

  12.1 Overview

  12.2 Marketed Skin Cancer Drug Profile


Each Drug Profile has Tables Representing Following Information:

• Alternate Names

• Originator & Owner

• Collaborator

• Technology Provider

• Licensee

• Highest Development Phase

• Indications

• Class

• Mechanism of Action

• ATC Code

• Designated Brand Name